The U.S. IPO market cleared four listings in a single week, spanning nuclear technology, biotechnology, critical materials, and specialty sectors. Each priced at or above the midpoint of guidance ranges. Combined, the cohort raised approximately $850 million in gross proceeds, marking the busiest single-week stretch for new issues since late Q3 2024.

Bullish, the crypto exchange backed by Thomas Farley and Peter Thiel's Founders Fund, priced 18 million shares at $16.00 each—above the expected $14.00-$15.00 range—raising $288 million. Shares opened at $18.50 on NYSE and closed the debut session at $19.12, a 19.5% first-day gain. The company operates a regulated digital asset exchange with CFTC approval and reported $47 million in Q3 revenue. A nuclear technology SPAC, Oklo Inc., completed a reverse merger and began trading under ticker OKLO, effectively raising $306 million through a concurrent PIPE. Oklo holds DOE site permits for small modular reactor deployment and is backed by Sam Altman. A biotech targeting rare metabolic disorders, Travere Therapeutics spin-out Kinetik, priced 12 million shares at $17.00, raising $204 million. The fourth debut, a critical materials processor focused on rare earth separation, priced 3.2 million shares at $16.00 and trades thinly on Nasdaq.

The week's activity reflects allocator appetite for exposure to three secular themes: energy transition infrastructure, digital asset regulatory clarity, and orphan drug economics. All four issuers had institutional anchor orders in place before pricing. Bookrunners included Goldman Sachs, Morgan Stanley, and Jefferies. The Oklo transaction is particularly notable—it bypassed traditional IPO mechanics entirely, opting for a de-SPAC structure with a $306 million PIPE led by Altman personally and several climate-focused family offices. The playbook suggests sponsors are routing capital-intensive, long-development assets through SPAC mergers rather than conventional S-1 processes. Bullish's pricing above range signals that crypto infrastructure—distinct from token issuance—can access public equity markets at reasonable valuations when paired with regulatory licensing. The company's $1.9 billion post-money valuation prices it at roughly 10x trailing revenue, in line with Coinbase's early trading multiples.

Allocators should track three follow-on events. First, Oklo's DOE site permit timeline—construction milestones are expected in Q2 2025, and any delay will reprice the equity. Second, Bullish's quarterly active user metrics, due in early February 2025; the company needs to demonstrate user growth outside its core Asian base to justify the premium multiple. Third, the biotech debut's Phase III data readout, scheduled for mid-2025. If positive, secondary offerings from this cohort will likely follow within 90-120 days of each debut, standard for capital-intensive issuers.

The $850 million week represents 18% of Q4 IPO volume to date. Three more issuers filed confidentially in the past ten days.